{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:11:18Z","timestamp":1790424678640,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","transplantation-proceedings.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.transproceed.2015.11.028","type":"journal-article","created":{"date-parts":[[2016,5,24]],"date-time":"2016-05-24T23:40:24Z","timestamp":1464133224000},"page":"806-808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Complement Inhibition for Prevention and Treatment of Antibody-Mediated Rejection in Renal Allograft Recipients"],"prefix":"10.1016","volume":"48","author":[{"given":"S.C.","family":"Jordan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kahwaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2015.11.028_bib1","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","article-title":"Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence","volume":"12","author":"Sellar\u00e9s","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2015.11.028_bib2","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/nrneph.2012.81","article-title":"The impact of donor-specific anti-HLA antibodies on late kidney allograft failure","volume":"8","author":"Loupy","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.transproceed.2015.11.028_bib3","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/01.TP.0000438636.52085.50","article-title":"Regulation of anti-HLA antibody-dependent natural killer cell activation by immunosuppressive agents","volume":"97","author":"Shin","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2015.11.028_bib4","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1302506","article-title":"Complement-binding anti-HLA antibodies and kidney-allograft survival","volume":"369","author":"Loupy","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2015.11.028_bib5","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1172\/JCI72273","article-title":"Complement as a multifaceted modulator of kidney transplant injury","volume":"124","author":"Cravedi","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.transproceed.2015.11.028_bib6","first-page":"273","article-title":"Compstatin: a complement inhibitor on its way to clinical application","volume":"632","author":"Ricklin","year":"2008","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.transproceed.2015.11.028_bib7","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa0805538","article-title":"Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema","volume":"363","author":"Zuraw","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2015.11.028_bib8","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/SHK.0b013e31825bf40e","article-title":"C1 inhibitor suppresses the endotoxic activity of a wide range of lipopolysaccharides and interacts with live gram-negative bacteria","volume":"38","author":"Mejia","year":"2012","journal-title":"Shock"},{"key":"10.1016\/j.transproceed.2015.11.028_bib9","doi-asserted-by":"crossref","first-page":"6462","DOI":"10.4049\/jimmunol.174.10.6462","article-title":"A\u00a0direct role for C1 inhibitor in regulation of leukocyte adhesion","volume":"174","author":"Cai","year":"2005","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.transproceed.2015.11.028_bib10","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1161\/STROKEAHA.112.660340","article-title":"C1-inhibitor protects from brain ischemia-reperfusion injury by combined antiinflammatory and antithrombotic mechanisms","volume":"43","author":"Heydenreich","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.transproceed.2015.11.028_bib11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/TP.0000000000000592","article-title":"A\u00a0Phase I\/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients","volume":"99","author":"Vo","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2015.11.028_bib12","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/ajt.13168","article-title":"Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year","volume":"15","author":"Cornell","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2015.11.028_bib13","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1600-6143.2011.03757.x","article-title":"Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients","volume":"11","author":"Stegall","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2015.11.028_bib14","unstructured":"Alexion Pharmaceuticals. Alexion provides update on phase 2 clinical trial with eculizumab in antibody mediated rejection (AMR) in living-donor kidney transplant recipients, http:\/\/news.alexionpharma.com\/press-release\/company-news\/alexion-provides-update-phase-2-clinical-trial-eculizumab-antibody-mediat;\u00a02015."},{"key":"10.1016\/j.transproceed.2015.11.028_bib15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1600-6143.2008.02451.x","article-title":"The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection","volume":"9","author":"Locke","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2015.11.028_bib16","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1111\/j.1432-2277.2011.01290.x","article-title":"Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation","volume":"24","author":"Biglarnia","year":"2011","journal-title":"Transpl Int"},{"key":"10.1016\/j.transproceed.2015.11.028_bib17","article-title":"Outcomes of eculizumab therapy for treatment of refractory antibody mediated rejection with thrombotic microangiopathy","author":"Wongsaroj","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2015.11.028_bib18","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1097\/TP.0000000000000525","article-title":"Factors predicting risk for antibody-mediated rejection and\u00a0graft loss\u00a0in highly human leukocyte antigen sensitized patients transplanted after desensitization","volume":"99","author":"Vo","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2015.11.028_bib19","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1097\/TP.0000000000000184","article-title":"Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts","volume":"98","author":"Burbach","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2015.11.028_bib20","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/TP.0000000000000298","article-title":"Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation","volume":"98","author":"Orandi","year":"2014","journal-title":"Transplantation"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134516001305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134516001305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T20:20:50Z","timestamp":1536697250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134516001305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0041134516001305"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2015.11.028","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complement Inhibition for Prevention and Treatment of Antibody-Mediated Rejection in Renal Allograft Recipients","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2015.11.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}